An integrated computational and experimental study uncovers FUT9 as a metabolic driver of colorectal cancer

Metabolic alterations play an important role in cancer and yet, few metabolic cancer driver genes are known. Here we perform a combined genomic and metabolic modeling analysis searching for metabolic drivers of colorectal cancer. Our analysis predicts FUT9, which catalyzes the biosynthesis of Ley glycolipids, as a driver of advanced‐stage colon cancer. Experimental testing reveals FUT9's complex dual role; while its knockdown enhances proliferation and migration in monolayers, it suppresses colon cancer cells expansion in tumorspheres and inhibits tumor development in a mouse xenograft models. These results suggest that FUT9's inhibition may attenuate tumor‐initiating cells (TICs) that are known to dominate tumorspheres and early tumor growth, but promote bulk tumor cells. In agreement, we find that FUT9 silencing decreases the expression of the colorectal cancer TIC marker CD44 and the level of the OCT4 transcription factor, which is known to support cancer stemness. Beyond its current application, this work presents a novel genomic and metabolic modeling computational approach that can facilitate the systematic discovery of metabolic driver genes in other types of cancer.

[1]  D. Sabatini,et al.  Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.

[2]  M. Hung,et al.  Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cells , 2016, Nature Communications.

[3]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[4]  S. Hakomori.  Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. , 1996, Cancer research.

[5]  V. Dixit,et al.  Ubiquitin in the activation and attenuation of innate antiviral immunity , 2016, The Journal of experimental medicine.

[6]  K. Kinzler,et al.  Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. , 1991, Science.

[7]  Michael F. Clarke,et al.  Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.

[8]  L. Ricci-Vitiani,et al.  Colon cancer stem cells , 2007, Gut.

[9]  Eytan Ruppin,et al.  A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration , 2014, Molecular Systems Biology.

[10]  John D Potter,et al.  Transcription Factor 7–like 2 Polymorphism and Colon Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[11]  Aarash Bordbar,et al.  A Systems Approach to Predict Oncometabolites via Context-Specific Genome-Scale Metabolic Networks , 2014, PLoS Comput. Biol..

[12]  Hans Clevers,et al.  The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. , 2011, Cell stem cell.

[13]  T. Wakano,et al.  Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma. , 2001, International journal of oncology.

[14]  V. Weaver,et al.  Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells , 2016, The Journal of experimental medicine.

[15]  C. Feschotte,et al.  Endogenous viruses: insights into viral evolution and impact on host biology , 2012, Nature Reviews Genetics.

[16]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[17]  S. Hsu,et al.  C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells , 2006, Oncogene.

[18]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[19]  J. Nielsen,et al.  Identification of anticancer drugs for hepatocellular carcinoma through personalized genome‐scale metabolic modeling , 2014, Molecular systems biology.

[20]  J. Lloreta,et al.  EphB–ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells , 2007, Nature Genetics.

[21]  M. Kurimoto,et al.  Ley glycolipid acts as a co‐factor for tumor procoagulant activity , 1997, International journal of cancer.

[22]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[23]  J. Esko,et al.  The sweet and sour of cancer: glycans as novel therapeutic targets , 2005, Nature Reviews Cancer.

[24]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[25]  Emanuel J. V. Gonçalves,et al.  Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition , 2016, Nature.

[26]  이연수.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[27]  C. Morrison,et al.  PTEN mutations are common in sporadic microsatellite stable colorectal cancer , 2004, Oncogene.

[28]  Udo Schumacher,et al.  Relevance of βGal–βGalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients , 2015, Breast Cancer Research and Treatment.

[29]  Natapol Pornputtapong,et al.  Reconstruction of Genome-Scale Active Metabolic Networks for 69 Human Cell Types and 16 Cancer Types Using INIT , 2012, PLoS Comput. Biol..

[30]  S. Haan,et al.  Tumor-Initiating Cells: a criTICal review of isolation approaches and new challenges in targeting strategies , 2017, Molecular Cancer.

[31]  S. Chiou,et al.  Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. , 2010, Cancer research.

[32]  G. Church,et al.  Analysis of optimality in natural and perturbed metabolic networks , 2002 .

[33]  M. Schachner,et al.  Expression of glycogenes in differentiating human NT2N neurons. Downregulation of fucosyltransferase 9 leads to decreased Lewis(x) levels and impaired neurite outgrowth. , 2012, Biochimica et biophysica acta.

[34]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[35]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[36]  B. Delahunt,et al.  Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. , 2002, Cancer research.

[37]  R. DiPaola,et al.  BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer , 2016, Clinical Cancer Research.

[38]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[39]  D. Steindler,et al.  Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. , 2009, Cancer research.

[40]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[41]  E. Fearon.  Genetic alterations underlying colorectal tumorigenesis. , 1992, Cancer surveys.

[42]  Jeffrey T. Chang,et al.  Anchorage-independent cell growth signature identifies tumors with metastatic potential , 2009, Oncogene.

[43]  Hiroshi Tanaka,et al.  Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, microarray and gene expression profile. , 2012, Cancer genomics & proteomics.

[44]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[45]  C. Blanpain,et al.  Unravelling cancer stem cell potential , 2013, Nature Reviews Cancer.

[46]  Hung-Ming Wang,et al.  Molecular Chaperones as a Common Set of Proteins That Regulate the Invasion Phenotype of Head and Neck Cancer , 2011, Clinical Cancer Research.

[47]  Andrew T. Chan,et al.  Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk , 2008, Cancer Causes & Control.

[48]  K. Shitara,et al.  Alpha1,3-fucosyltransferase IX (Fut9) determines Lewis X expression in brain. , 2003, Glycobiology.

[49]  Eytan Ruppin,et al.  Model-based identification of drug targets that revert disrupted metabolism and its application to ageing , 2013, Nature Communications.

[50]  Bernhard O. Palsson,et al.  Context-Specific Metabolic Networks Are Consistent with Experiments , 2008, PLoS Comput. Biol..

[51]  Monica L. Mo,et al.  Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.

[52]  J. Morgado-Díaz,et al.  The role of N-glycans in colorectal cancer progression: potential biomarkers and therapeutic applications , 2015, Oncotarget.

[53]  Y. Rombouts,et al.  Glycosylation characteristics of colorectal cancer. , 2015, Advances in cancer research.

[54]  Eyal Gottlieb,et al.  Inborn and acquired metabolic defects in cancer , 2011, Journal of Molecular Medicine.

[55]  Michal A. Kurowski,et al.  Transcriptome Profile of Human Colorectal Adenomas , 2007, Molecular Cancer Research.

[56]  B. Lim,et al.  Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression , 2016, Nature Communications.

[57]  W F Bodmer,et al.  The ABC of APC. , 2001, Human molecular genetics.

[58]  Jukka-Pekka Mecklin,et al.  SMAD4 as a Prognostic Marker in Colorectal Cancer , 2005, Clinical Cancer Research.

[59]  S. Hakomori,et al.  Novel fucolipids of human adenocarcinoma: characterization of the major Ley antigen of human adenocarcinoma as trifucosylnonaosyl Ley glycolipid (III3FucV3FucVI2FucnLc6). , 1986, The Journal of biological chemistry.

[60]  J. Wrana,et al.  Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. , 2011, Cancer research.

[61]  O. Demin,et al.  The Edinburgh human metabolic network reconstruction and its functional analysis , 2007, Molecular systems biology.

[62]  M. Taketo,et al.  Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene , 2007, Journal of Cell Science.

[63]  M. Król,et al.  Identification and characterization of cancer stem cells in canine mammary tumors , 2016, Acta Veterinaria Scandinavica.

[64]  E. Gottlieb,et al.  Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer , 2006, Oncogene.

[65]  Larry A. Sklar,et al.  Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia , 2016, Cell.

[66]  H. Ishida,et al.  A novel β1,3‐N‐acetylglucosaminyltransferase (β3Gn‐T8), which synthesizes poly‐N‐acetyllactosamine, is dramatically upregulated in colon cancer , 2005, FEBS letters.

[67]  H. Lenz,et al.  Molecular prognostic markers in locally advanced colon cancer. , 2007, Clinical colorectal cancer.

[68]  Jeffrey D Orth,et al.  What is flux balance analysis? , 2010, Nature Biotechnology.

[69]  H. O’Neill,et al.  Oncogenesis and cancer stem cells: current opinions and future directions , 2009, Journal of cellular and molecular medicine.

[70]  Takeo Iwama,et al.  Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis , 1999, Oncogene.

[71]  S. Su,et al.  IDH mutations in glioma and acute myeloid leukemia. , 2010, Trends in molecular medicine.

[72]  Masahide Takahashi,et al.  Increased expression levels of ppGalNAc-T13 in lung cancers: Significance in the prognostic diagnosis , 2016, International journal of oncology.